If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
104
results.
Updated on
24/10/2026 [09:02:00]
Absstract of: AU2025231677A1
Disclosed in the present invention are an antibody targeting TL1A and the use thereof. The antibody of the present invention can be used for blocking the interaction between TL1A and DR3, is helpful for achieving the purpose of intervention from the early stages of inflammation, inhibits immune cells such as effector T cells to release cytokines for promoting an inflammatory response, and provides more possibilities for treatment methods for IBD patients or other TL1A-related diseases.
Absstract of: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Absstract of: WO2026217813A1
Induced pluripotent stem cells (iPSCs) were generated from patients with Crohn's disease and directed to human intestinal organoids, from which and subsequently purify the mesenchymal cell component was purified and obtained. Individual patient's iPSC-derived mesenchymal cells were used to screen for potential anti-fibrotic therapies.
Absstract of: WO2026217925A1
Provided herein are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having inflammatory bowel disease. In particular, the disclosure relates to using assays that detect peptidoglycan recognition proteins and/or tissue inhibitor of metalloproteinase-2 in a biological sample (for example a stool sample) of the subject as diagnostic and prognostic biomarker assays in IBD.
Absstract of: AU2025229905A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Absstract of: WO2026215387A1
The present invention relates to a method for the diagnosis of an IgE-mediated disease based on the measurement of the amount, or relative proportion, of IgE proteoforms resulting from the proteolytic cleavage of IgE by proteases at one or more specific sites within one or both ε heavy chains.
Absstract of: US20260309591A1
A system and method for monitoring gastrointestinal health using a passive air-sampling device positioned on top of a toilet tank. The device comprises a gas sensor array, environmental sensors, and a processor configured to collect data during a user's bowel movement. Gas signatures are analyzed using machine learning to identify users and assess gut health without requiring stool handling. A proprietary health score is generated from sensor and contextual data and displayed to the user via a mobile application. The system continuously improves by associating sensor patterns with user-reported symptom classifications and retraining its algorithms to detect gastrointestinal conditions. The neural-network-enabled gas sensor produces multidimensional digital fingerprints of sampled gas compositions, enabling condition screening based on complex patterns rather than predefined biomarkers. The application includes a goal-setting chatbot using cognitive behavioral therapy methods to promote habit change. Data processing is distributed across on-device inference, edge AI, and cloud services.
Absstract of: US20260309721A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: US20260306484A1
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
Absstract of: WO2026207459A1
Methods comprising administering a therapeutically effective amount of H2S scavenger, and optionally butyrate, as described herein, to a subject who has an inflammatory gut condition, e.g., Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), colonic Crohn's Disease (CD), pouchitis and inflammation after proctocolectomy with ileal pouch-anal anastomosis (j-pouch surgery) to treat UC, irritable bowel disease (IBD), and subjects who have those conditions who are at risk of developing colon/colorectal cancer.
Absstract of: US20260298945A1
Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.
Absstract of: US20260297673A1
0000 Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.
Absstract of: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Absstract of: WO2026196294A1
The present invention provides improved management of IBD treatment by anti-TNF-alpha antibodies comprising glycans having Neu5Ac instead of non-human Neu5Gc glycosylation or by antibodies in which Neu5Ac was added. The present invention further provides methods for monitoring levels of anti-glycan antibodies in IBD patients and prediction of development of secondary immune mediated inflammatory autoimmune diseases, mediated by these antibodies.
Absstract of: US20260285908A1
0000 Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Absstract of: US20260272993A1
The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.
Absstract of: US20260276634A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Absstract of: US20260275426A1
Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.
Absstract of: US20260265827A1
Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.
Absstract of: US20260265841A1
In some embodiments, provided is a method for identifying a stool sample with an altered microbiome associated with IBD with disease above TI comprising the steps of: a) determining the relative abundance of a set of bacterial species in the stool sample; b) comparing the relative abundance of each bacterial species in the set of bacterial species from the individual with the relative abundance of each bacterial species in the set of bacterial species in a reference data set to generate a risk score; and c) determining the stool sample as having an altered microbiome associated with IBD with disease above the TI if the risk score is higher than a cutoff value. Other embodiments are described herein. In some embodiments, provided methods, kits, products and uses of compositions provide a cost-effective, non-invasive method to support clinical decision making, and hence to help improve disease management regarding disease above TI.
Absstract of: WO2026185407A1
The present invention is directed to compositions, including post-biotic compositions, comprising cereal gruel fermented by Lactobacillus plantarum 299 and/or Lactobacillus plantarum 299v®. The compositions are useful for 5 treating diseases in human beings, including liver diseases, as well as gastrointestinal diseases and inflammatory conditions related to liver diseases. Disease treatment and treatment efficacies may be monitored based on the development in selected patient groups of one or more biomarkers, including intestinal fatty acid-binding protein (I-FABP) and C-reactive protein 10 (CRP).
Absstract of: AU2025237849A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Absstract of: AU2025228200A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Absstract of: US20260265828A1
Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.
Nº publicación: AU2026220293A1 10/09/2026
Applicant:
PACIFIC MYCO BIOSCIENCES LTD
Pacific MYCO Biosciences Ltd.
Absstract of: AU2026220293A1
Abstract The present invention relates to methods of immune modulation. In particular, the present invention relates to regulation of inflammation and immune responses by modulation of ABCF1. Modulation of ABCF1 may be useful in the treatment of sepsis, autoimmune diseases, cancer or infections. ug u g
BOPI
Electronic site
